RNA polymerase II subunit J4 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored POLR2J4 profile across patient tissues and cancer cell-line models. POLR2J4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, POLR2J4 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, POLR2J4 RNA expression shows 17,393 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, THCA, and ACC as cancer lineages where POLR2J4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2J4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2J4 survival associations across molecular data types. POLR2J4 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2J4 RNA expression–survival associations across cancer types. High POLR2J4 expression shows unfavorable associations in UVM, ACC and LGG, but favorable associations in KIRP, PAAD and THYM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for POLR2J4 RNA expression.
This table summarizes POLR2J4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for POLR2J4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2J4 shows lower tumor expression in THCA, KIRP, KIRC and COAD and higher tumor expression in LIHC and BLCA. The THCA box plot shows higher POLR2J4 RNA expression in normal versus tumor tissue (log2 FC = −1.294, t-test p < 0.001).
This table shows molecular features associated with POLR2J4 in patient tissues and cancer cell lines. In patient samples, POLR2J4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2J4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in OVARY and NCI60_ALL.
